"substrain: ATCC 25922"	"characteristics_ch1.1"
"genotype/variation: wild-type"	"characteristics_ch1.2"
"Agilent Feature Extraction Software (v 8.5.1.1) was used for background subtraction and LOWESS normalization."	"data_processing.1"
"RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany)."	"extract_protocol_ch1.1"
"E. coli ATCC 25922 (wild-type) and EC14, EC19, EC24 (LLQR) isogenic strains were tested to evaluate the global response to relevant fix concentration of ciprofloxacin (1 mg/L, breakpoint for reduced susceptibility according to CLSI). All of them were susceptible to quinolones according to CLSI breakpoints. (CLSI, n.d.) Cultures were started from single colonies and grown overnight in 25 ml of LB. These cell were diluted 1:100 and growth to cell concentration of 4x108 cells/ml (OD600 nm=0.4, exponential phase) for treatment. Three biological replicates per genotype were incubated at 1 mg/L of ciprofloxacin during 60 minutes (that means 250xMIC for E. coli ATCC 25922, 8xMIC for EC14, 2xMIC for EC19 and 1xMIC for EC24). Approximately 109 cells (2 ml) were taken for RNA isolation."	"growth_protocol_ch1.1"
"Escherichia coli ATCC 25922"	"organism_ch1.1"
"Exponential cells (DO600=0,4)"	"source_name_ch1.1"
"Wild-type E. coli ATCC 25922 replicate 1"	"title.1"
"Biological replicates per genotype were incubated at 1 mg/L of ciprofloxacin during 60 minutes (that means 250xMIC for E. coli ATCC 25922, 8xMIC for EC14, 2xMIC for EC19 and 1xMIC for EC24)."	"treatment_protocol_ch1.1"
"substrain: ATCC 25922"	"characteristics_ch1.1"
"genotype/variation: wild-type"	"characteristics_ch1.2"
"E. coli ATCC 25922 (wild-type) and EC14, EC19, EC24 (LLQR) isogenic strains were tested to evaluate the global response to relevant fix concentration of ciprofloxacin (1 mg/L, breakpoint for reduced susceptibility according to CLSI). All of them were susceptible to quinolones according to CLSI breakpoints. (CLSI, n.d.) Cultures were started from single colonies and grown overnight in 25 ml of LB. These cell were diluted 1:100 and growth to cell concentration of 4x108 cells/ml (OD600 nm=0.4, exponential phase) for treatment. Three biological replicates per genotype were incubated at 1 mg/L of ciprofloxacin during 60 minutes (that means 250xMIC for E. coli ATCC 25922, 8xMIC for EC14, 2xMIC for EC19 and 1xMIC for EC24). Approximately 109 cells (2 ml) were taken for RNA isolation."	"growth_protocol_ch1.1"
"Escherichia coli ATCC 25922"	"organism_ch1.1"
"Exponential cells (DO600=0,4)"	"source_name_ch1.1"
"Biological replicates per genotype were incubated at 1 mg/L of ciprofloxacin during 60 minutes (that means 250xMIC for E. coli ATCC 25922, 8xMIC for EC14, 2xMIC for EC19 and 1xMIC for EC24)."	"treatment_protocol_ch1.1"